Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Pier Luigi Zinzani, Robert Chen, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)950-954
Number of pages5
JournalLeukemia and Lymphoma
Volume61
Issue number4
DOIs
Publication statusPublished - 20-03-2020

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Zinzani, P. L., Chen, R., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Lin, J., Nahar, A., Balakumaran, A., & Moskowitz, C. H. (2020). Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leukemia and Lymphoma, 61(4), 950-954. https://doi.org/10.1080/10428194.2019.1702178